The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 16, Issue 3, 2017, Pages 401-409

  Garinis, Angela C ^a,b   Cross, Campbell P ^a,e   Srikanth, Priya ^e   Carroll, Kelly ^a   Feeney, M Patrick ^a,b   Keefe, Douglas H ^c   Hunter, Lisa L ^d   Putterman, Daniel B ^a,b   Cohen, David M ^e   Gold, Jeffrey A ^e   Steyger, Peter S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NATIONAL CENTER FOR REHABILITATIVE AUDITORY RESEARCH   (United States)

^c BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE; AIR CONDUCTION; ANTIBIOTIC THERAPY; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; BONE CONDUCTION; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG EFFECT; ELECTRONIC HEALTH RECORD; FEMALE; HEARING; HEARING ACUITY; HEARING IMPAIRMENT; HEARING TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE EAR DISEASE; MIDDLE EAR PRESSURE; PERCEPTION DEAFNESS; PREVALENCE; TYMPANOMETRY; BACTERIAL INFECTION; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PURE TONE AUDIOMETRY; SEX FACTOR; TIME; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AMIKACIN; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; SEX FACTORS; TIME; TOBRAMYCIN; UNITED STATES; VANCOMYCIN;

EID: 85013661075     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.01.006     Document Type: Article

References (50)

1. [1] Martins, L.M., Camargos, P.A., Becker, H.M., Becker, C.G., Guimaraes, R.E., Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol 74:5 (2010), 469–473.
2. [2] Mulheran, M., Degg, C., Burr, S., Morgan, D.W., Stableforth, D.E., Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 45:9 (2001), 2502–2509.
3. [3] Cheng, A.G., Johnston, P.R., Luz, J., Uluer, A., Fligor, B., Licameli, G.R., et al. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg 141:1 (2009), 86–90.
4. [4] Prayle, A., Smyth, A.R., Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med, 16(6), 2010, 604.
5. [5] Moore, R.D., Smith, C.R., Lietman, PS, Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149 (1984), 23–30.
6. [6] Md Daud, M.K., Mohamadl, H., Haron, A., Rahman, N.A., Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions. B-ENT, 10(1), 2014, 53.
7. [7] Hirose, K., Li, S.Z., Ohlemiller, K.K., Ransohoff, R.M., Systemic lipopolysaccharide induces cochlear inflammation and exacerbates the synergistic ototoxicity of kanamycin and furosemide. J Assoc Res Otolaryngol 15:4 (2014), 555–570.
8. [8] Brummett, R.E., Fox, K.E., Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 33:6 (1989), 797–800.
9. [9] Moore, R.D., Smith, C.R., Lietman, P.S., Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149:1 (1984), 23–30.
10. [10] Riethmueller, J., Ballmann, M., Schroeter, T.W., Franke, P., von Butler, R., Claass, A., et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 37:5 (2009), 424–431.
11. [11] Pilcher, O.B., Teixeira, V.N., de Oliveira, MW, Scattolin, I., Piltcher, S.L., The prevalence of neurosensorineural hearing loss among cystic fibrosis patients from Hospital de Clinicals de Porto Alegre. Int J Pediatr Otorhinolaryngol, 2003, 939–941.
12. [12] Tarshish, Y., Huang, L., Jackson, F.I., Edwards, J., Fligor, B., Wilkins, A., et al. Risk factors for hearing loss in patients with cystic fibrosis. J Am Acad Audiol 27:1 (2016), 6–12.
13. [13] Geyer, L.B., Menna Barreto, S.S., Weigert, L.L., Teixeira, A.R., High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients. Braz J Otorhinolaryngol 81:6 (2015), 589–597.
14. [14] Fausti, S.A., Henry, J.A., Schaffer, H.I., Olson, D.J., Frey, R.H., McDonald, W.J., High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 165:6 (1992), 1026–1032.
15. [15] Yoon, P.J., Price, M., Gallagher, K., Fleisher, B.E., Messner, A.H., The need for long-term audiologic follow-up of neonatal intensive care unit (NICU) graduates. Int J Pediatr Otorhinolaryngol 67:4 (2003), 353–357.
16. [16] Gurtler, N., Schmuziger, N., Kim, Y., Mhatre, A.N., Jungi, M., Lalwani, A.K., Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides. Laryngoscope 115:4 (2005), 640–644.
17. [17] Al-Malky, G., Suri, R., Dawson, S.J., Sirimanna, T., Kemp, D., Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol 50:2 (2011), 112–122.
18. [18] Mick, P., Westerberg, B.D., Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol 36:5 (2007), 257–263.
19. [19] Bailie, G.R., Neal, D., Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:5 (1988), 376–386.
20. [20] Scheenstra, R.J., Heijerman, H.G., Zuur, C.L., Touw, D.J., Rijntjes, E., No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Otolaryngol 130:2 (2010), 253–258.
21. [21] Mulheran, M., Hyman-Taylor, P., Tan, K.H., Lewis, S., Stableforth, D., Knox, A., et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 50:7 (2006), 2293–2299.
22. [22] Van Meter, D.J., Corriveau, M., Ahern, J.W., Lahiri, T., A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 44:4 (2009), 325–329.
23. [23] Nordstrom, L., Lerner, S.A., Single daily dose therapy with aminoglycosides. J Hosp Infect 18:Suppl. A (1991), 117–129.
24. [24] Tran Ba Huy, P., Deffrennes, D., Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol 105:5–6 (1988), 511–515.
25. [25] Gilbert, D.N., Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35:3 (1991), 399–405.
26. [26] Rybak, M.J., Abate, B.J., Kang, S.L., Ruffing, M.J., Lerner, S.A., Drusano, G.L., Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:7 (1999), 1549–1555.
27. [27] Cystic Fibrosis Foundation, Cystic Fibrosis Foundation patient registry annual data report 2013 to the center directors. [Bethesda, Maryland], 2014.
28. [28] ANSI, Author, (eds.) Specification for instruments to measure aural acoustic impedance and admittance (aural acoustic immittance) S3.39-1987 R2007, 2007 [New York].
29. [29] ANSI, Author, (eds.) Specifications for audiometers (ANSI 3.6-1996), 1996 [New York].
30. [30] ANSI, Specification for audiometers (ANSI S3.6-2010). 2010, Author, New York.
31. [31] Cox, R.M., McDaniel, D.M., Reference equivalent threshold levels for pure tone and 13 octare noise bands: insert earphone and TDH 49 earphone. J Acoust Soc Am 79:2 (1986), 443–446.
32. [32] Poulsen, T., Reference thresholds for EARTONE 3A insert earphones. Scand Audiol 20:3 (1991), 205–207.
33. [33] Frank, T., High-frequency hearing thresholds in young adults using a commercially available audiometer. Ear Hear 11:6 (1990), 450–454.
34. [34] Carhart, R., Jerger, J., Preferred method for clinical determination of pure-tone thresholds. J Speech Hear Disord 24 (1959), 330–345.
35. [35] ASHA, Scope of practice in audiology [scope of practice]. Available from: www.asha.org/policy, 2004.
36. [36] Audiology AAO, Guidelines and standards adult diagnostics. Available from: http://www.audiology.org/publications/guidelines-and-standards, 2016.
37. [37] Sinxadi, P., Blockman, M., Drug-induced ototoxicity.(clinical pharmacology) (clinical report). CME Your SA J CPD, 27(8), 2009, 372.
38. [38] Bates, D.E., Beaumont, S.J., Baylis, B.W., Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 36:3 (2002), 446–451.
39. [39] Bruniera, F.R., Saviolli, L.R.M., Bacci, M.R., Feder, D., da Luz Goncalves Pedreira, M., Sorgini Peterlini, M.A., et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 19:4 (2015), 694–700.
40. [40] Chiodo, A.A., Alberti, P.W., Experimental, clinical and preventive aspects of ototoxicity. Eur Arch Otorhinolaryngol 251:7 (1994), 375–392.
41. [41] Pleasants, R.A., Michalets, E.L., Williams, D.M., Samuelson, W.M., Rehm, J.R., Knowles, M.R., Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 40:1 (1996), 186–190.
42. [42] Gatell, J.M., San Miguel, J.G., Zamora, L., Araujo, V., Bonet, M., Bohe, M., et al. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrob Agents Chemother 23:6 (1983), 897–901.
43. [43] Matz, G.J., Lerner, S.A., Prospective studies of aminoglycoside ototoxicity in adults. Lerner, S.A., Matz, G.J., Hawkins, J.E., (eds.) Aminoglycoside ototoxicity, 1981, Little, Brown and Company, Boston, 327–336.
44. [44] Brummett, R.E., Fox, K.E., Bendrick, T.W., Himes, D.L., Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the Guinea pig. J Antimicrob Chemother 4:Suppl. A (1978), 73–83.
45. [45] Lubin, J.H.C.N., Wichmann, H.E., Schaffrath-Rosario, A., Alavanja, M.C., Cigarette smoking and lung cancer: modeling effect modification of total exposure and intensity. Epidemiology 18 (2007), 639–648.
46. [46] Rademaker-Lakhai, J.M., Crul, M., Zuur, L., Baas, P., Beijnen, J.H., Simis, Y.J., et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24:6 (2006), 918–924.
47. [47] Rodriguez-Valiente, A., Trinidad, A., Garcia Berrocal, J.R., Gorriz, C., Ramirez Camacho, R., Extended high-frequency (9–20kHz) audiometry reference thresholds in 645 healthy subjects. nt J Audiol 53:8 (2014), 531–545.
48. [48] Frank, T., High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear 22:2 (2001), 161–168.
49. [49] Koo, J.W., Quintanilla-Dieck, L., Jiang, M., Liu, J., Urdang, Z.D., Allensworth, J.J., et al. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. Sci Transl Med, 7(298), 2015, 298ra118.
50. [50] Cross, C.P., Liao, S., Urdang, Z.D., Srikanth, P., Garinis, A.C., Steyger, P.S., Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure. Int J Pediatr Otorhinolaryngol 79:11 (2015), 1915–1919.